Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 26/September/2016, 10.54 pm

Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 26/September/2016, 10.54 pm

Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 26/September/2016, 10.54 pm 150 150 Dr Boomi's Genom-2-Discovery Center

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10),

Significance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.

This study suggests, for the first time, a Natural product-based cardiac regeneration therapy. (+)-Syringaresinol, by increasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.

(+)-Syringaresinol, isolated from Panax ginseng berry, promotes myocardial function after myocardial infarction

(+)-Syringaresinol, isolated from Panax ginseng berry, promotes myocardial function after heart attack

Thus, by treating myocardial patients with (+)-Syringaresinol or its analogues, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “(+)-Syringaresinol or its analogues” may be used to improve cardiac function after myocardial infarction

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org or newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Natural product therapy for Myocardial Infarction: (+)-Syringaresinol, isolated from Panax ginseng berry, improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 26/September/2016, 10.54 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation

Amount: $300

Satisfaction-guaranteed-if-not-refunded

Undisclosed information: How (+)-Syringaresinol increases the expression of PNUTS/PPP1R10